Resolution Pharmaceuticals

Resolution Therapeutics is a clinical-stage biotechnology company pioneering the development of macrophage cell therapies to treat inflammatory and fibrotic diseases. Based in the United Kingdom and backed by Syncona, the company leverages a proprietary platform to engineer macrophages with enhanced anti-fibrotic and pro-regenerative properties. Its lead candidate, RTX-001, is an autologous macrophage therapy currently being evaluated in the Phase 1/2 EMERALD clinical trial for patients with liver cirrhosis. By targeting the underlying causes of organ damage, Resolution Therapeutics aims to provide a transformative alternative to liver transplantation. The company operates out of London and Edinburgh, collaborating closely with the University of Edinburgh's Centre for Regenerative Medicine.